LARIMAR THERAPEUTICS INC

Larimar Therapeutics files first BLA module for accelerated FDA approval of nomlabofusp, a promising Friedreich’s ataxia therapy, sparking investor interest and stock moves.

Larimar Therapeutics Inc, a clinical-stage biotech company, successfully closed a $60 million public offering, navigating a mixed market reaction as it advances its mission to develop treatments for rare complex diseases.

Larimar Therapeutics Inc. has announced a public offering to raise capital for its research and development efforts in protein replacement therapy and other treatments for rare diseases.

Larimar Therapeutics, Inc. is a biotech company dedicated to developing treatments for rare complex diseases, offering hope to patients and families affected by these conditions.